Zacks Investment Research upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a research report released on Friday morning. They currently have $3.75 target price on the biotechnology company’s stock.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Several other research analysts also recently weighed in on the stock. HC Wainwright set a $6.00 target price on shares of ZIOPHARM Oncology and gave the stock a buy rating in a report on Tuesday, November 13th. Raymond James raised shares of ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 target price for the company in a report on Thursday, November 15th. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a strong sell rating to a sell rating in a report on Saturday, November 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. ZIOPHARM Oncology has a consensus rating of Buy and a consensus price target of $4.92.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts forecast that ZIOPHARM Oncology will post -0.51 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of ZIOP. Marshall Wace LLP bought a new position in ZIOPHARM Oncology in the 3rd quarter worth $115,000. Jane Street Group LLC bought a new position in ZIOPHARM Oncology in the 3rd quarter worth $161,000. Raymond James & Associates boosted its holdings in ZIOPHARM Oncology by 168.3% in the 2nd quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock worth $176,000 after buying an additional 36,568 shares during the period. MetLife Investment Advisors LLC boosted its holdings in ZIOPHARM Oncology by 77.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock worth $199,000 after buying an additional 28,734 shares during the period. Finally, Belpointe Asset Management LLC bought a new position in ZIOPHARM Oncology in the 3rd quarter worth $262,000. 40.07% of the stock is owned by institutional investors.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Recommended Story: What is systematic risk?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.